Literature DB >> 16613857

Cyclin D1-cdk4 induce runx2 ubiquitination and degradation.

Run Shen1, Xiumei Wang, Hicham Drissi, Fang Liu, Regis J O'Keefe, Di Chen.   

Abstract

Runx2 is a Runt domain transcription factor involved in the activation of genes encoding osteoblast and chondrocyte-specific proteins. Runx2 activity is regulated by transcriptional and post-transcriptional mechanisms. The functional significance of the post-translational modification of Runx2 has not been fully defined. We show that cyclin D1-Cdk4 induce Runx2 degradation in an ubiquitination-proteasome-dependent manner. Mutagenesis of Runx2 serine-472, a consensus Cdk site, to alanine increases the half-life of Runx2 and causes loss of sensitivity to cyclin D1-induced Runx2 degradation. The targeted Runx2 degradation by cyclin D1 identifies a novel mechanism through which Runx2 activity is regulated coordinately with the cell cycle machinery in bone cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613857      PMCID: PMC2649830          DOI: 10.1074/jbc.M603439200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  cdk1- and cdk2-mediated phosphorylation of MyoD Ser200 in growing C2 myoblasts: role in modulating MyoD half-life and myogenic activity.

Authors:  M Kitzmann; M Vandromme; V Schaeffer; G Carnac; J C Labbé; N Lamb; A Fernandez
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts.

Authors:  Hiroyuki Kaneki; Ruolin Guo; Di Chen; Zhenqiang Yao; Edward M Schwarz; Ying E Zhang; Brendan F Boyce; Lianping Xing
Journal:  J Biol Chem       Date:  2005-12-22       Impact factor: 5.157

3.  Phosphorylation of nuclear MyoD is required for its rapid degradation.

Authors:  A Song; Q Wang; M G Goebl; M A Harrington
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

4.  Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia.

Authors:  S Mundlos; F Otto; C Mundlos; J B Mulliken; A S Aylsworth; S Albright; D Lindhout; W G Cole; W Henn; J H Knoll; M J Owen; R Mertelsmann; B U Zabel; B R Olsen
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

5.  Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

Authors:  T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

6.  Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development.

Authors:  F Otto; A P Thornell; T Crompton; A Denzel; K C Gilmour; I R Rosewell; G W Stamp; R S Beddington; S Mundlos; B R Olsen; P B Selby; M J Owen
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

7.  Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism.

Authors:  K Inoue; C J Sherr
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

8.  Regulation of chondrocyte differentiation by Cbfa1.

Authors:  I S Kim; F Otto; B Zabel; S Mundlos
Journal:  Mech Dev       Date:  1999-02       Impact factor: 1.882

Review 9.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

10.  Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues.

Authors:  M Sato; E Morii; T Komori; H Kawahata; M Sugimoto; K Terai; H Shimizu; T Yasui; H Ogihara; N Yasui; T Ochi; Y Kitamura; Y Ito; S Nomura
Journal:  Oncogene       Date:  1998-09-24       Impact factor: 9.867

View more
  58 in total

1.  Stabilization of RNT-1 protein, runt-related transcription factor (RUNX) protein homolog of Caenorhabditis elegans, by oxidative stress through mitogen-activated protein kinase pathway.

Authors:  Kiho Lee; Jiwon Shim; Jaebum Bae; Young-Joon Kim; Junho Lee
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

Review 2.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

3.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Authors:  Anastasia R Goloudina; Kan Tanoue; Arlette Hammann; Eric Fourmaux; Xavier Le Guezennec; Dmitry V Bulavin; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

4.  Dimorphic effects of Notch signaling in bone homeostasis.

Authors:  Feyza Engin; Zhenqiang Yao; Tao Yang; Guang Zhou; Terry Bertin; Ming Ming Jiang; Yuqing Chen; Lisa Wang; Hui Zheng; Richard E Sutton; Brendan F Boyce; Brendan Lee
Journal:  Nat Med       Date:  2008-02-24       Impact factor: 53.440

Review 5.  Signaling networks that control the lineage commitment and differentiation of bone cells.

Authors:  Carrie S Soltanoff; Shuying Yang; Wei Chen; Yi-Ping Li
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

Review 6.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

7.  Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype.

Authors:  Adam D Pierce; Ian E Anglin; Michele I Vitolo; Maria T Mochin; Karen F Underwood; Simeon E Goldblum; Sravya Kommineni; Antonino Passaniti
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

8.  SOX9 keeps growth plates and articular cartilage healthy by inhibiting chondrocyte dedifferentiation/osteoblastic redifferentiation.

Authors:  Abdul Haseeb; Ranjan Kc; Marco Angelozzi; Charles de Charleroy; Danielle Rux; Robert J Tower; Lutian Yao; Renata Pellegrino da Silva; Maurizio Pacifici; Ling Qin; Véronique Lefebvre
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-23       Impact factor: 11.205

9.  The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

Authors:  Margaretha van der Deen; Jacqueline Akech; Tao Wang; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

10.  PTHrP prevents chondrocyte premature hypertrophy by inducing cyclin-D1-dependent Runx2 and Runx3 phosphorylation, ubiquitylation and proteasomal degradation.

Authors:  Ming Zhang; Rong Xie; Wei Hou; Baoli Wang; Run Shen; Xiumei Wang; Qing Wang; Tianhui Zhu; Jennifer H Jonason; Di Chen
Journal:  J Cell Sci       Date:  2009-04-07       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.